凱普生物(300639.SZ)：擬通過凱普健康管理開展婦女兒童醫院建設項目
格隆匯8月10日丨凱普生物(300639.SZ)公佈，公司擬通過全資子公司廣東凱普醫療健康管理有限公司(“凱普健康管理”)投資建設運營一所體制先進、就醫體驗舒適、以婦女兒童保健為特色的民營營利性醫院，充分整合公司醫療健康管理資源，融合公司在核酸分子診斷系列產品及高端醫學特檢優勢資源，充分運用公司在宮頸癌檢測的龍頭地位及多年行業積澱、生殖系統/遺傳基因缺陷/癌症基因檢測/用藥伴隨診斷的特色技術/產品資源優勢，重點打造婦產系列、兒科系列、腫瘤系列等臨牀重點專科，通過該項目的運營加快凱普集團打造“中國婦幼健康第一品牌”的戰略。
項目投資總額預計不超過10億元，首期投資金額不超過7.5億元。公司自有資金投入佔比不超過60%、項目專項貸款投入佔比約為40%，根據實際需求可引進外部戰略機構合作。
該項目建設用地位於潮州市潮安區，位於廣東省東部，南連汕頭經濟特區，西與揭陽市交界，北與梅州市接壤，靠近機場和高鐵站，交通便利，市政條件齊備，可與以潮州市為中心的服務半徑近300公里範圍內的城市包括粵東三市、梅州市、贛州市和漳州市6個高端醫療資源較為缺乏的城市打造一小時生活圈，對改善周邊地區高端醫療資源匱乏的情況，提升粵東地區居民就醫就診服務水平具有良好的地理優勢。
該項目順應國家健康中國戰略，符合國家醫療衞生事業發展規劃及大力支持社會辦醫的政策導向，基於潮州市、粵東地區乃至閩南、贛南地區優質醫療衞生服務供給嚴重不足帶來的巨大市場需求，將提升區域居民就醫就診服務水平。
同時，該項目依託公司總部資源建設運營，未來將打造為婦幼健康領域的研究應用示範基地、人才培訓與專家交流基地，運營成熟後將申請作為國家醫療器械臨牀試驗機構，成為公司體外診斷試劑、醫學檢驗服務研究開發的臨牀試驗基地，對加速推進凱普生物研發進程、“核酸99”產品戰略實施、第三方特檢項目開發及應用，醫學檢驗檢測業務的發展均具有重要戰略意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
